InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Immunovant, Inc.

IMVT Clue Score35
United States Fiscal year ends March CIK 0001764013
$29.48 -3.25% Close, 12 Oct 2026
Alert on the numbers Alert on insider trades
Price $29.48 +216.99% Close, 12 Oct 2026

Closing prices at the end of each trading day, from 19 Dec 2019. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Net income
Fiscal year 2019Net income−28.6Fiscal year 2020Net income−66.4Fiscal year 2021Net income−107.4EPS, diluted−1.22Fiscal year 2022Net income−156.7EPS, diluted−1.43Fiscal year 2023Net income−211.0EPS, diluted−1.71Fiscal year 2024Net income−259.3EPS, diluted−1.88Fiscal year 2025Net income−413.8EPS, diluted−2.73Fiscal year 2026Net income−505.6EPS, diluted−2.77
FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Net income −28.6 −66.4 −107.4 −156.7 −211.0 −259.3 −413.8 −505.6
Growth
EPS, diluted n/a n/a −1.22 −1.43 −1.71 −1.88 −2.73 −2.77
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2019Operating cash flow−28.5Capital expenditure−0.1Free cash flow−28.6Fiscal year 2020Operating cash flow−53.4Capital expenditure−0.0Free cash flow−53.4Fiscal year 2021Operating cash flow−83.3Capital expenditure−0.2Free cash flow−83.5Fiscal year 2022Operating cash flow−106.1Capital expenditure−0.3Free cash flow−106.4Fiscal year 2023Operating cash flow−188.2Capital expenditure−0.2Free cash flow−188.4Fiscal year 2024Operating cash flow−214.2Capital expenditure−0.4Free cash flow−214.6Fiscal year 2025Operating cash flow−375.9Capital expenditure−0.8Free cash flow−376.6Fiscal year 2026Operating cash flow−407.3Capital expenditure−0.0Free cash flow−407.3
FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Operating cash flow −28.5 −53.4 −83.3 −106.1 −188.2 −214.2 −375.9 −407.3
Capital expenditure −0.1 −0.0 −0.2 −0.3 −0.2 −0.4 −0.8 −0.0
Free cash flow −28.6 −53.4 −83.5 −106.4 −188.4 −214.6 −376.6 −407.3
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2019Cash7.0Shareholders’ equity7.3Fiscal year 2020Cash100.6Shareholders’ equity94.1Fiscal year 2021Cash400.1Shareholders’ equity391.5Fiscal year 2022Cash493.8Shareholders’ equity469.8Fiscal year 2023Cash376.5Shareholders’ equity362.5Fiscal year 2024Cash635.4Shareholders’ equity617.8Fiscal year 2025Cash714.0Shareholders’ equity707.4Fiscal year 2026Cash902.1Shareholders’ equity852.6
FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Cash 7.0 100.6 400.1 493.8 376.5 635.4 714.0 902.1
Shareholders’ equity 7.3 94.1 391.5 469.8 362.5 617.8 707.4 852.6

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2026 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending March, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2019 31 Mar 2019 FY2020 31 Mar 2020 FY2021 31 Mar 2021 FY2022 31 Mar 2022 FY2023 31 Mar 2023 FY2024 31 Mar 2024 FY2025 31 Mar 2025 FY2026 31 Mar 2026
Revenue and profit
25.7 47.9 68.6 101.8 n/a n/a n/a n/a
2.7 18.2 39.5 54.2 48.0 57.3 77.2 76.2
−28.6 −66.3 −107.8 −156.8 −211.0 −258.8 −412.9 −505.4
0.0 0.1 −0.4 −0.1 0.0 0.6 0.9 0.2
−28.6 −66.4 −107.4 −156.7 −211.0 −259.3 −413.8 −505.6
Growth
Per share
n/a n/a −1.22 −1.43 −1.71 −1.88 −2.73 −2.77
n/a n/a −1.22 −1.43 −1.71 −1.88 −2.73 −2.77
Growth
n/a n/a 87.8 109.7 123.1 138.1 151.6 182.4
n/a n/a 87.8 109.7 123.1 138.1 151.6 182.4
Growth +25.0% +12.2% +12.2% +9.8% +20.4%

Five years in brief

Worked out from the figures above, not from a press release
  • The diluted share count rose 107.9% in five years, which is dilution.
  • A net loss in 8 of 8 years on file.